Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,... see more

GREY:ATBPF - Post Discussion

View:
Post by Marky1 on Feb 11, 2021 2:54pm

Royalties

Could someone please explain to me about Royalties...Let's say it cost 100$ for ANTIBE to make a bottle of Otenaproxesul....It is sold in China, let's say for 300$...so ANTIBE makes a profit of 200$...so how do Royalties fit into all this? Please explain how it works...
Comment by Layth1990 on Feb 11, 2021 2:59pm
what i understand, royalties is like a comission  from total sales, revenues or net profit (depends). in the future nuance will produce and commercialize our drug. if royalties for example is 15% from the total sales, that means if they sold 1B a year, antibe will get 150m. if i'm wrong , feel free to correct me 
Comment by 3burtc on Feb 11, 2021 3:14pm
Yes! There market is about 10 billion a year and our drug could get half of that for a whopping 5 billion giving us $750 million annually. Not bad for just 10% of the global pain market.
Comment by bringon10bagger on Feb 11, 2021 6:20pm
WOW, they're sweet royalty amount for just 10% global sales....that just compounds buyout value for any big pharma.....a $4B buyout they can get they can get payback in 5 years from just Nuances royalty.......that just seems $4B is minute for a complete buyout...proves you can never dream big enough with what may happen here.
Comment by Pragmatist on Feb 11, 2021 3:12pm
Royalties normally are based on the sales  of the drug by the licensee.  Antibe receives x% of these revenues from the licensee.  Holdings receives 15 of Antibe's take. Someone previously mentioned that Holdings would also receive 15% of the upfront payment (and other milestones??)  That's not what the license arrangements say in the available documents. But in a way ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities